Related Experiment Video
Updated: May 28, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
[Coagulation factor XIII: more than just a fibrin stabilizer]
N Messaoudi1, F Lamaalmi, M Chakour
1Laboratoire d'Hématologie, Hôpital Militaire d'Instruction Mohammed V, Rabat, Maroc.
Annals of Burns and Fire Disasters
|October 13, 2011
Summary
Coagulation factor XIII, also known as the fibrin stabilizing factor, plays a crucial role in wound healing and scar formation. Despite its known function since 1960, its importance in treating burn patients remains underappreciated by medical professionals.
Area of Science:
- Hematology
- Wound Healing
- Biochemistry
Context:
- Coagulation factor XIII (FXIII), or fibrin stabilizing factor, has a well-documented role in hemostasis since its identification in 1923.
- Its specific involvement in the scarring process was elucidated in 1960.
- However, this critical function appears to be overlooked by hematologists and clinicians managing burn injuries.
Purpose:
- To re-examine and highlight the significant role of coagulation factor XIII in the complex process of scar formation.
- To bridge the knowledge gap concerning FXIII's function in wound healing, particularly in the context of burn patient care.
- To underscore the need for greater awareness and understanding of FXIII's contribution to tissue repair.
Summary:
- This review focuses on coagulation factor XIII (FXIII), a key enzyme in the coagulation cascade.
- While FXIII's role in stabilizing fibrin clots is established, its specific contribution to scar tissue development is less recognized.
- The paper aims to illuminate FXIII's function in scarring, emphasizing its relevance for clinicians treating patients with significant tissue damage.
Impact:
- Increased clinical awareness of coagulation factor XIII's role in scarring can lead to improved patient outcomes in wound healing.
- A deeper understanding may facilitate the development of targeted therapies to optimize scar formation and reduce complications.
- This research seeks to re-establish FXIII as a vital factor in regenerative medicine and trauma care.
Related Concept Videos
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:06Coagulation
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...